PMV Pharmaceuticals (PMVP) Projected to Announce Earnings on Wednesday

Key Points

• PMV Pharmaceuticals is expected to report Q3 2026 results before markets open Wednesday, November 11. Analysts forecast a loss of $0.31 per share; the earnings call is scheduled for November 13 at 9:30 a.m. ET.
• In its prior quarter, PMV reported a loss of $0.34 per share, better than the consensus estimate of a $0.39 loss. Analysts expect losses of $1.20 per share for the current fiscal year and $0.81 for the next.
• Analysts have a consensus Moderate Buy rating and an average price target of $4.33, compared with shares at $1.40 in the article. Price targets cited range from $3 to $5.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.05. On average, analysts expect PMV Pharmaceuticals to post ($1.20) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.

PMV Pharmaceuticals Stock Performance

Shares of PMVP stock opened at $1.40 on Wednesday. The stock has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.30. The firm has a market capitalization of $75.00 million, a P/E ratio of -0.99 and a beta of 1.52. PMV Pharmaceuticals has a 52-week low of $1.02 and a 52-week high of $1.91.

Wall Street Analysts Forecast Growth

PMVP has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of PMV Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of PMV Pharmaceuticals in a research note on Friday, September 4th. Weiss Ratings raised PMV Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 24th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of PMV Pharmaceuticals in a report on Wednesday, July 8th. They set a "buy" rating and a $3.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $4.33.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc is a clinical-stage precision oncology company focused on developing therapies that target cancer-causing mutations in the tumor suppressor protein p53. The company aims to discover and develop small-molecule medicines designed to restore the normal tumor-suppressing function of mutant p53 proteins.

PMV's lead product candidate is rezatapopt, also known as PC14586, an investigational oral therapy designed to selectively target the p53 Y220C mutation. This mutation occurs in a range of solid tumors, and rezatapopt is being evaluated for its potential to reactivate the altered p53 protein and inhibit cancer-cell growth.

Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals is advancing rezatapopt through clinical development in patients with advanced solid tumors containing the p53 Y220C mutation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.